Citadel LP Raises Stake in BioMarin (BMRN) to 5.52% 04-26-2007 11:27:02 AM
Citadel LP disclosed a 5.52% stake (5.575 million shares) in Biomarin. This is up from the 43,657 share stake the firm held at the quarter ended 12/31/06.
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates.
Started by market-guru Kenneth Griffin in his Harvard dorm room in 1987, Citadel has become one of the world's largest hedge funds.
Market Data 
Markets 
AI
